Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Preferred Stock Liabilities: 2014-2015

  • KalVista Pharmaceuticals' Preferred Stock Liabilities was N/A to $39.6 million in Q1 2015 from the same period last year, while for Mar 2015 it was $39.6 million, marking a year-over-year change of. This contributed to the annual value of $58.6 million for FY2016, which is 128.88% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Preferred Stock Liabilities stood at $39.6 million for Q1 2015, which was down 0.00% from $39.6 million recorded in Q4 2014.
  • In the past 5 years, KalVista Pharmaceuticals' Preferred Stock Liabilities registered a high of $39.6 million during Q4 2014, and its lowest value of $39.6 million during Q4 2014.
  • For the 2-year period, KalVista Pharmaceuticals' Preferred Stock Liabilities averaged around $39.6 million, with its median value being $39.6 million (2015).